The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 445 participants.

Also called NCT04192747

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 445 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04192747
Other papers using this trial's data
  • Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent: 2-Year Outcomes From BIOADAPTOR RCT JACC. Cardiovascular interventions, 2025-04-28 DOI, PubMed 40057888

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Germany, Japan, New Zealand (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04192747. Randomized; double masking; primary purpose treatment. Start 2020-12-16 (actual); primary completion 2023-02-28 (actual). Results posted on 2024-10-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
Acronym
BIOADAPTOR RCT
Condition
Coronary Artery Stenosis
Condition
Coronary Disease
Condition
Coronary Stenosis
Lead sponsor
Elixir Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct04192747
Content hash
271993634da79808748e00abd87df4c6661ac487db765e1fcb46f10eaae09d4c